Kaplan-Meier probability of overall survival of patients with acute glucocorticoid-refractory GVHD.

Survival after therapy with visilizumab is shown separately for patients treated on the single-dose (solid line, n = 11) and on multidose (striped line, n = 6) regimens. The difference between the 2 groups is significant at P = .03.